Journal profile · ONCOLOGY-OBSTETRICS & GYNECOLOGY
Journal of Gynecologic Oncology
ISSN 2005-0380 · eISSN 2005-0399 · Korean Society of Gynecologic Oncology and Colposcopy · SOUTH KOREA · Quarterly · Founded 2008
Journal of Gynecologic Oncology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.11; fully open access; APC about USD 1,000; median 191 days to acceptance (89 articles, last 24 months); community-reported acceptance: fairly easy; 132 articles in 2025; indexed in SCIE and Scopus; the journal's website says it has moved to a new publisher.
The journal's website says it has moved to a new publisher: JGO provides the electronic backup and preservation of access to the journal content in the event the journal is no longer published by archiving in PubMed Central. Source ↗Publisher website ·
Scope
Aims, scope and focus
Journal of Gynecologic Oncology is published by Korean Society of Gynecologic Oncology and Colposcopy and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment and Cervical Cancer and HPV Research, together about 56.6% of its articles. Its main subfields are Obstetrics and Gynecology. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Gynecologic Oncology (JGO) is the official journal of the Asian Society of Gynecologic Oncology, the Korean Society of Gynecologic Oncology, and the Japan Society of Gynecologic Oncology. Published bimonthly, JGO disseminates high-quality basic, translational, clinical, and health-systems research that advances care for patients with gynecologic cancers. Focus areas - Epidemiology, prevention, early detection, molecular pathology, and tumor biology - Phase I–III clinical trials, registry and real-world evidence, and translational research - Genomics/’omics’, immuno-oncology, biomarkers, and precision medicine - Surgical, radiation, and systemic therapies (including multimodal approaches) - Patient-reported outcomes, survivorship, health equity, cost-effectiveness, and policy studies - Digital health, AI/machine learning, imaging analytics, bioinformatics, and methodological innovation Publication principles - Scientific rigor, ethical standards, transparency, and reproducibility - Encourages data/code/protocol sharing and accepts preprints - Authors should follow relevant reporting guidelines (e.g., CONSORT, PRISMA, STROBE) Note - Breast cancer research is outside JGO’s scope. Indexing - Indexed in major databases (e.g., MEDLINE/PubMed, PubMed Central, Web of Science/SCIE, Scopus, EMBASE). ·
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY-OBSTETRICS & GYNECOLOGY
Editor-in-chief Dong Hoon SuhPublisher website
Editorial board by country: 9 in mainland China (about 10%); most named South Korea 35, Japan 14, Mainland China 9, Thailand 7, Taiwan, China 6 (87 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Endometrial and Cervical Cancer TreatmentsMedicine27%
- Ovarian cancer diagnosis and treatmentMedicine18.7%
- Cervical Cancer and HPV ResearchMedicine10.8%
- Uterine Myomas and TreatmentsMedicine5.2%
- Gynecological conditions and treatmentsMedicine4.7%
- PARP inhibition in cancer therapyMedicine4.4%
- Intraperitoneal and Appendiceal MalignanciesMedicine3.8%
- Reproductive Biology and FertilityMedicine2.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Obstetrics & Gynecology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Obstetrics & Gynecology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Obstetrics & Gynecology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPublisher website
Other: Index Medicus
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.11LetPub ·
- Impact factor (publisher) 2025
- 4.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.9Publisher website ·
- CiteScore 2026-06
- 5.8LetPub ·
- SJR 2026-06
- 1.26LetPub ·
- SNIP 2026-06
- 1.45LetPub ·
- h-index
- 30LetPub ·
- h-index
- 71OpenAlex ·
- i10-index
- 815OpenAlex ·
- 2-year mean citedness
- 2.85OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 115LetPub ·
Articles by year OpenAlex count · 1,666 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 133 | 133 | 52 |
| 2025 | 132 | 132 | 296 |
| 2024 | 129 | 129 | 773 |
| 2023 | 97 | 97 | 1,164 |
| 2022 | 92 | 92 | 1,140 |
| 2021 | 94 | 94 | 1,347 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
191 daysMedian, submission to acceptance · P25–P75 140 days – 256 days
- Acceptance to online
- median 34 days (89 articles)
- Submission to online
- median 237 days
- Sample
- 89 articles with submission and acceptance dates (310 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher) 2022
- 18.1%Publisher website ·
- Submission to first decision 2022
- 22 daysPublisher website ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 1,000 | No | CC BY-NC | |
| LetPub | No APC | No | — | |
| Publisher website | USD 100 / USD 1,000 | — | — |
Other charges and waivers (author guidelines)
- Other fees
- USD 100
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare11 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≤ 6
- Manuscript length
- ≤ 3,500 words
- Reference style
- Vancouver
- Templates
- Word
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Required
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
- Not considered
- case reports
Article types accepted12
- clinical trial protocol7) Clinical Trial Protocol offers a protocol for the prospective clinical trial, whether phase II or III.Length not stated
- commentary • editorial6) Commentary • Editorial provides commentary and analysis on a current issue JGO article and is usually invited by the Editor-in-Chief.Length not stated
- erratum/corrigendum10) Erratum/Corrigendum/Length not stated
- expert opinion• Expert Opinion is an invited perspectives in gynecologic oncology, dealing on very active areas of research, fresh insights and debates.Length not stated
- letter to the editor• Letter to the Editor may be in response to a published article, or a short, free-standing piece expressing an opinion is recommended.Length not stated
- meeting report9) Meeting Report is usually solicited by the Editor-in-Chief among the outstanding meetings.Length not stated
- original article1) Original Article (including Meta-analysis) reports results of basic and clinical investigations.Length not stated
- position statement5) Position Statement describes one side of the arguable viewpoint and provides direction for a society or organization.Length not stated
- practice guideline4) Practice Guideline offers updated version of evidence-based recommendations to help with optimizing patient care.Length not stated
- review article2) Review Article is usually solicited by the Editor-in-Chief and describe concise review on subjects of importance to medical researchers.Length not stated
- special report3) Special Report addresses timely issues of special interest to readers and gynecologic oncologic society.Length not stated
- video article8) Video Article presents novel surgical techniques, treatments or interventions for clinical care or research in gynecologic oncology.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints, Self-archiving, Trial registration / reporting guidelines
- AI use 20) Use of artificial intelligence (AI)
The JGO follows the ICMJE recommendations regarding the use of AI (https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). According to the ICMJE recommendations on "Roles & Responsibilities," authors who utilized such technology should explain its use in both the cover letter and the appropriate section of the submitted work, if…
Source ↗Publisher website ·- Authorship 3) Authorship
Authorship per ICMJE. Model summary
In accordance with the ICMJE, each author should have participated sufficiently in the work to take public responsibility for the content (http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). All other contributors who do not meet sufficient criteria for authorship should be noted in the Acknowledgments section. Otherwise, any …
Source ↗Publisher website ·- Conflicts of interest 5) Conflict of interest
All contributors to JGO are required to disclose financial and other relationships with entities that have investment, licensing, or other commercial interests in the subject matter under consideration in their article. These disclosures should include, but are not limited to, relationships with pharmaceutical and biotechnology companies, device manufacturers, or other commercial entities whose pr…
Source ↗Publisher website ·- Data availability 8) Data sharing statement
Data sharing per ICMJE. Model summary
JGO accepts the ICMJE Recommendations for data sharing statement policy (http://icmje.org/icmje-recommendations.pdf). All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines from 1 Feb 2019.
Source ↗Publisher website ·- License & copyright 10) Copyright and permissions
All published papers become the permanent property of the Asian Society of Gynecologic Oncology, the Korean Society of Gynecologic Oncology, and the Japan Society of Gynecologic Oncology. Upon publication of an article, a representative author should upload a Copyright Transfer Form. Please download Copyright Transfer Form.pdf in the journal homepage (https://ejgo.org/index.php?body=instructions).…
Source ↗Publisher website ·- Open access 1) Open access
Open access under CC BY license. Model summary
JGO is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Permission must be requested from the Editorial Office of JGO to use tables or figures appearing in the journal in other periodicals, books, or …
Source ↗Publisher website ·- Peer review V. Editorial and Peer Review Process
The Editor selects peer reviewers by using reviewer suggested by authors, by recommendation of the Editorial Board members or from the specialist database owned by the Editorial Board. Acceptance of the manuscript is decided, based on the critiques and recommended decision of the reviewers. A reviewer's decision is made as “Accept,” “Minor revisions,” “Major revisions”, and “Reject”. If there is m…
Source ↗Publisher website ·- Preprints 17) Preprint Policy
JGO will consider publication of manuscripts that contain information previously posted on any recognized, not-for-profit, preprint platform, such as medRxiv, arXiv, bioRxiv. Authors must retain copyright to such postings. Preprint information must be disclosed at submission so reviewers and editors can evaluate the preprinted information and compare it with the submitted manuscript. Please note t…
Source ↗Publisher website ·- Self-archiving
Archived in PubMed Central. Model summary
The full text of JGO has been archived in PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/journals/883/) from the volume 19, 2008.
Source ↗Publisher website ·- Trial registration / reporting guidelines 11) Reporting guidelines
JGO has incorporated specific guidelines for reporting randomized controlled trials (i.e., CONSORT), meta-analyses and systematic reviews of randomized controlled trials (i.e., PRISMA), meta-analyses and systematic reviews of observational studies (i.e., MOOSE), observational studies (i.e., STROBE), studies of diagnostic accuracy (i.e., STARD), tumor marker prognostic studies (i.e., REMARK), quali…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Korean Society of Gynecologic Oncology and Colposcopy
- Country or region
- SOUTH KOREA
- Language
- English
- Frequency
- Quarterly
- Founded
- 2008
- ISSN
- 2005-0380
- Electronic ISSN
- 2005-0399
- Society / sponsor
- Asian Society of Gynecologic Oncology
- Latest issue on the website
- Volume 37, Issue 4 (July 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Gynecologic Oncology
What CAS zone is Journal of Gynecologic Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Gynecologic Oncology is in Zone 2 of Medicine, and in Zone 3 of the minor category Obstetrics & Gynecology / Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Gynecologic Oncology?
The latest impact factor listed by LetPub is 4.11; CiteScore 5.8, h-index 71.
How long does peer review take at Journal of Gynecologic Oncology?
Based on the dates recorded on 89 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 191 days (interquartile range 140–256 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 18.1% (2022). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Gynecologic Oncology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≤ 6; Manuscript length: ≤ 3,500 words; Reference style: Vancouver; Templates: Word; First submission: Free format: the journal's layout is not required; Suggested reviewers: Required; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Gynecologic Oncology based?
Of the 87 board members whose country the journal's board page names, 9 (about 10%) are in mainland China; the countries named most often are South Korea (35), Japan (14) and Mainland China (9). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Gynecologic Oncology?
According to LetPub and DOAJ records, Journal of Gynecologic Oncology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists PMC; that list has not been checked against each database.
Is Journal of Gynecologic Oncology open access, and what is the APC?
Journal of Gynecologic Oncology is a fully open-access journal. APC about USD 1,000.
Sources and updates
The facts on this page come from LetPub, Publisher website, DOAJ, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .